Basel, Switzerland, November 16, 2026
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant) in combination with everolimus for treating adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval applies to patients whose disease has returned during or after completing endocrine-based adjuvant therapy or progressed following at least one endocrine-based treatment regimen in the metastatic setting. This regulatory milestone introduces an important treatment option for patients with advanced breast cancer who develop resistance to conventional hormone therapies. Wilserdly is a next-generation oral selective estrogen receptor degrader (SERD) designed to target estrogen receptor signalling, one of the important biological pathways involved in hormone-sensitive breast cancer. The combination with everolimus provides a dual-pathway treatment approach, addressing both estrogen receptor activity and the mTOR signalling pathway. Importantly, the treatment offers an entirely oral administration option, eliminating the need for injections associated with certain existing endocrine therapies.
Wilserdly Targets ESR1 Mutations and Hormone Resistance
The FDA approval addresses a significant unmet medical need among patients with hormone receptor-positive advanced breast cancer. ESR1 mutations are an important mechanism of resistance to endocrine therapy, allowing cancer cells to continue growing despite treatments designed to block estrogen signalling. According to Roche, these mutations affect up to 40% of patients with hormone receptor-positive metastatic breast cancer and can contribute to disease progression following initial treatment. Wilserdly works by binding to estrogen receptors, blocking estrogen activity and promoting the degradation of the receptor protein. This mechanism helps suppress estrogen receptor signalling, which plays a critical role in the growth of many breast cancer cells. When combined with everolimus, an mTOR inhibitor, the treatment targets two different biological pathways associated with cancer progression and treatment resistance. The combination is intended for patients whose tumours carry ESR1 mutations confirmed through an FDA-authorised diagnostic test. By introducing this targeted oral treatment combination, Roche aims to expand therapeutic options for patients whose disease has progressed following previous endocrine-based treatment. The approval also strengthens the company’s oncology portfolio and advances its research into precision-based breast cancer therapies.
Phase III evERA Trial Demonstrates 62% Risk Reduction
The FDA decision is supported by positive results from Roche’s pivotal Phase III evERA Breast Cancer clinical trial (NCT05306340), which evaluated the efficacy and safety of giredestrant combined with everolimus compared with standard endocrine therapy combined with everolimus. The randomized, open-label, multicentre study included patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer whose disease had progressed following previous CDK4/6 inhibitor and endocrine therapy treatment. The trial achieved its primary endpoint, demonstrating a statistically significant improvement in progression-free survival with the Wilserdly combination. Among patients with ESR1-mutated breast cancer, Wilserdly plus everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus. The treatment demonstrated a stratified hazard ratio of 0.38, with a 95% confidence interval of 0.27–0.54 and a p-value of less than 0.0001. These findings indicate a substantial improvement in disease control for the studied patient population. The clinical results were published in the New England Journal of Medicine, providing peer-reviewed evidence supporting the regulatory decision. The findings also highlight the potential of targeting estrogen receptor degradation alongside mTOR inhibition to address treatment resistance in advanced breast cancer.
Roche Advances Wilserdly Development Across Breast Cancer
Beyond the latest FDA approval, Roche is continuing to evaluate Wilserdly across multiple stages and treatment settings of breast cancer through an extensive clinical development programme. The company has also submitted a New Drug Application seeking approval of Wilserdly as an adjuvant treatment for adults with ER-positive, HER2-negative stage I, II and III breast cancer who have an intermediate to high risk of disease recurrence. This application is supported by findings from the Phase III lidERA Breast Cancer study and has been accepted by the FDA under Priority Review. The regulatory decision is expected by November 30, 2026. If approved, Wilserdly could become the first selective estrogen receptor degrader approved for both adjuvant and advanced ER-positive breast cancer settings. Roche is also investigating the medicine in additional Phase III studies to assess its potential across different breast cancer populations and treatment combinations. The company continues to pursue regulatory submissions and development activities in markets outside the United States. Overall, the FDA approval of Wilserdly represents a significant advancement in targeted breast cancer treatment, particularly for patients with ESR1 mutations and resistance to endocrine therapy. By combining an oral estrogen receptor degrader with an mTOR inhibitor, Roche is expanding treatment possibilities and strengthening its commitment to developing innovative oncology medicines.
Source: Roche press release



